Market closed
Scholar Rock/$SRRK
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Scholar Rock
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
Ticker
$SRRK
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
150
Website
Scholar Rock Metrics
BasicAdvanced
$4.2B
Market cap
-
P/E ratio
-$2.82
EPS
0.48
Beta
-
Dividend rate
Price and volume
Market cap
$4.2B
Beta
0.48
52-week high
$45.84
52-week low
$6.76
Average daily volume
1.2M
Financial strength
Current ratio
3.884
Quick ratio
3.561
Long term debt to equity
76.475
Total debt to equity
76.475
Interest coverage (TTM)
-35.50%
Management effectiveness
Return on assets (TTM)
-67.10%
Return on equity (TTM)
-183.07%
Valuation
Price to book
45.28
Price to tangible book (TTM)
45.28
Price to free cash flow (TTM)
-18.988
Growth
Earnings per share change (TTM)
-0.11%
3-year earnings per share growth (CAGR)
-6.13%
What the Analysts think about Scholar Rock
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Scholar Rock stock.
Scholar Rock Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Scholar Rock Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Scholar Rock News
AllArticlesVideos
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·1 week ago
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
Benzinga·4 weeks ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Scholar Rock stock?
Scholar Rock (SRRK) has a market cap of $4.2B as of December 22, 2024.
What is the P/E ratio for Scholar Rock stock?
The price to earnings (P/E) ratio for Scholar Rock (SRRK) stock is 0 as of December 22, 2024.
Does Scholar Rock stock pay dividends?
No, Scholar Rock (SRRK) stock does not pay dividends to its shareholders as of December 22, 2024.
When is the next Scholar Rock dividend payment date?
Scholar Rock (SRRK) stock does not pay dividends to its shareholders.
What is the beta indicator for Scholar Rock?
Scholar Rock (SRRK) has a beta rating of 0.48. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.